BioSpace News Archive

MitoSense Inc. in collaboration with Uppsala University, Elliott Mitochondrial Center, and the Sallie Astor Burdine Breast Foundation in Baton Rouge, Louisiana, USA, proudly announces a landmark scientific breakthrough in the field of mitochondrial preservation, a key element in mitochondrial transplantation therapies.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced an oral presentation and poster presentation at the Keystone Symposia on Emerging Cellular Therapies meeting, held from January 22 to 25, 2024 in Santa Fe, New Mexico.

Nikon Instruments Inc. is pleased to announce the establishment of the Nikon BioImaging Lab Lexington in Massachusetts, USA, where it will provide research and development functions as well as drug discovery support development services.

ESSA Pharma Inc. today announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 ASCO Genitourinary Cancers Symposium, taking place January 25 - 27, 2024, in San Francisco, CA.

The Scleroderma Research Foundation announces the appointment of Gregory Gordon, MD, JD as its first Chief Medical Officer.

Bloom Burton & Co. (“Bloom Burton”) is excited to announce the launch of the 2024 Bloom Burton Award and to open nomination submissions.

Vanda Pharmaceuticals announces the publication of an article on The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial.

Confluent Medical Technologies (Confluent) announced that it has partnered with ATI to invest more than $50 million over the next several years in ATI’s Nitinol melt and materials conversion infrastructure.

Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA ® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been dosed with UX701 across the three dose-escalation cohorts in Stage 1 of its pivotal Phase 1/2/3 Cyprus2+ study.